1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME
申请人:Kowa Company, Ltd.
公开号:EP2322505A1
公开(公告)日:2011-05-18
It is to provide a novel compound useful for preventing and/or treating diseases that involves 11β-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. It is an 1-adamantyl azetidin-2-one derivative represented by the following general formula (1) or salt thereof, or their solvate.
[wherein A ring represents C6-10 aryl group, 5- to 14-membered heteroaryl group, R1 is a hydrogen atom, halogen atom, C1-6 alkoxycarbonyl group, hydroxyl group, carboxyl group or carbamoyl group; R2 and R3 are the same or different and are a C1-6 alkyl groups R4, R5, and R6 are same or different, and are a hydrogen atom, halogen atom, C1-6 alkyl group, C1-6 alkoxy group, C6-10 aryl group, or R4 and R5, or R5 and R6 may together form a C1-3 alkylenedioxy group, R7 and R8 are the same of different and represent a hydrogen atom or C1-6 alkyl) group, or may together form a C3-6 cyclic hydrocarbon group, n represents an integer of 0 or 1]
本发明旨在提供一种新型化合物,用于预防和/或治疗涉及 11β- 羟基类
固醇脱氢酶 1 的疾病,特别是糖尿病、
胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、高血压、脂肪肝或代谢综合征。它是由以下通式(1)代表的 1-
金刚烷基氮杂
环丁烷-2-酮衍
生物或其盐,或它们的溶解物。
[其中 A 环代表 C6-10 芳基、5-14 元杂芳基,R1 是氢原子、卤素原子、C1-6 烷氧羰基、羟基、羧基或
氨基甲酰基;R4、R5 和 R6 相同或不同,是氢原子、卤素原子、C1-6 烷基、C1-6 烷氧基、C6-10 芳基,或 R4 和 R5,或 R5 和 R6 可共同形成 C1-3 烷二氧基,R7 和 R8 相同或不同,代表氢原子或 C1-6 烷基,或可共同形成 C3-6
环烃基,n 代表 0 或 1 的整数]。